<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110850">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01778465</url>
  </required_header>
  <id_info>
    <org_study_id>103330</org_study_id>
    <nct_id>NCT01778465</nct_id>
  </id_info>
  <brief_title>Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease</brief_title>
  <official_title>Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <authority>Canada: MOHTLC</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aspirin-Exacerbated Respiratory Disease, or AERD, consists of aspirin sensitivity, asthma
      and nasal polyps.  It is currently managed by chronic steroid use, multiple endoscopic sinus
      surgeries and/or aspirin desensitization. However, these treatments have potential adverse
      effects.

      A theory has been postulated that decreasing the level of dietary salicylates may help in
      long-term control of disease.  A current trial is in the works to evaluate the clinical
      outcomes of decreased salicylate, but measurements of biochemical markers of disease has not
      yet been done.  The hypothesis is that decreased dietary salicylates will result in a
      decrease in urinary salicylates and inflammatory markers of disease, cys-leukotrienes, which
      are typically elevated in this disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Urinary levels of Cys-Leukotrienes</measure>
    <time_frame>14 days after commencement</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary salicylate levels</measure>
    <time_frame>14 days after enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Rhinosinusitis</condition>
  <condition>Aspirin Exacerbated Respiratory Disease</condition>
  <condition>Asthma</condition>
  <condition>Aspirin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Low salicylate diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are to follow a low salicylate diet for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are to continue with a normal diet for one week.  There is then cross-over after one week for a further week into the intervention group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low salicylate diet</intervention_name>
    <arm_group_label>Low salicylate diet</arm_group_label>
    <other_name>Dietary salicylate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients

          -  Aspirin-exacerbated respiratory disease

        Exclusion Criteria:

          -  recent use of Prednisone or other systemic steroids (greater than 3 doses in past 3
             months)

          -  Endoscopic sinus surgery or polypectomy within the past 6 months

          -  Other significant systemic disease, including renal failure, or immunocompromised
             state.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leigh J Sowerby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson HRI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leigh J Sowerby, MD</last_name>
    <phone>519-646-6143</phone>
    <email>leigh.sowerby@sjhc.london.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leigh J Sowerby</last_name>
    </contact>
    <investigator>
      <last_name>Leigh J Sowerby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Rotenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krupal Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 26, 2013</lastchanged_date>
  <firstreceived_date>January 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Leigh Sowerby</investigator_full_name>
    <investigator_title>Assistant Professor, Otolaryngology</investigator_title>
  </responsible_party>
  <keyword>Chronic Rhinosinusitis</keyword>
  <keyword>Aspirin exacerbated respiratory disease</keyword>
  <keyword>Asthma</keyword>
  <keyword>Aspirin sensitivity</keyword>
  <keyword>Salicylate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
